Literature DB >> 16313757

[Mechanism linking atherosclerosis and type 2 diabetes: increased expression of scavenger receptor CD36 in monocytes].

Hong-Mei Zhang1, Xiao-Lian Zhang, Xin Zhou, Dong Li, Jin-Gang Gu, Juan-Juan Wu.   

Abstract

BACKGROUND: We investigated the pathogenesis of atherosclerosis in diabetes, and detected the expression of scavenger receptor CD36 in monocytes in patients with type 2 diabetes.
METHODS: According to the criteria by WHO, diabetic patients were classified into two groups: well controlled diabetic patients (WCP) and poorly controlled diabetic patients (PCP). The expression of CD36 protein and mRNA were evaluated by flow cytometry and reversal transcription polymerase chain reaction (RT-PCR). Plasma levels of accumulation of oxidized LDL (oxLDL) were directly measured by sandwich enzyme-linked immunosorbent assay (ELISA) method.
RESULTS: Flow cytometry and RT-PCR showed that the mean fluorescence intensity (MFI) of CD36 in monocyte and CD36 mRNA were significantly higher in the PCP and WCP in comparison with healthy controls (P<0.01). CD36 MFI and mRNA in the PCP were increased by 78% and 36% compared to the WCP. In both groups, CD36 MFI and mRNA were significantly higher in patients with diabetic atherosclerosis in comparison with those without diabetic atherosclerosis (P<0.05). No significant difference was found in CD14 expression between the groups (P>0.05). The concentrations of plasma oxLDL were higher in the PCP group compared to WCP and control group (P<0.05), whereas oxLDL average values did not differ significantly between WCP and control groups (P>0.05). In the WCP and PCP groups, oxLDL levels were higher in patients with diabetic atherosclerosis than those without diabetic atherosclerosis (P<0.05).
CONCLUSIONS: The increased expression of scavenger receptor CD36 may be one of the mechanism of accelerated atherosclerosis in diabetic. The poorly controlled diabetes patients are at higher risk for the vascular complications than the well controlled diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16313757

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  4 in total

1.  Increased CD36 expression signals monocyte activation among patients with type 2 diabetes.

Authors:  Yijuan Sun; Marina Scavini; Robert A Orlando; Glen H Murata; Karen S Servilla; Antonios H Tzamaloukas; Ronald Schrader; Edward J Bedrick; Mark R Burge; Nada A Abumrad; Philip G Zager
Journal:  Diabetes Care       Date:  2010-06-14       Impact factor: 19.112

2.  A Novel Index Using Soluble CD36 Is Associated with the Prevalence of Type 2 Diabetes Mellitus: Comparison Study with Triglyceride-Glucose Index.

Authors:  Ho Jin Kim; Jun Sung Moon; Il Rae Park; Joong Hee Kim; Ji Sung Yoon; Kyu Chang Won; Hyoung Woo Lee
Journal:  Endocrinol Metab (Seoul)       Date:  2017-09

3.  CD36 overexpression: a possible etiopathogenic mechanism of atherosclerosis in patients with prediabetes and diabetes.

Authors:  M D Lopez-Carmona; M C Plaza-Seron; A Vargas-Candela; F J Tinahones; R Gomez-Huelgas; M R Bernal-Lopez
Journal:  Diabetol Metab Syndr       Date:  2017-07-18       Impact factor: 3.320

4.  Platelet Activation and Platelet-Leukocyte Aggregates in Type I Diabetes Mellitus.

Authors:  Asmaa M Zahran; Omnia El-Badawy; Ismail L Mohamad; Deiaaeldin M Tamer; Safwat M Abdel-Aziz; Khalid I Elsayh
Journal:  Clin Appl Thromb Hemost       Date:  2018-10-11       Impact factor: 2.389

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.